Literature DB >> 35417043

Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity.

Khoa A Nguyen1, Madison J Keith1, Stephen B Keysar2, Spencer C Hall1, Anamol Bimali1, Antonio Jimeno2, Xiao-Jing Wang1,3, Christian D Young1.   

Abstract

Head and neck squamous cell carcinoma (HNSCC) is commonly associated with tobacco and alcohol consumption that induce a "precancerous field," with phosphoinositide 3-kinase (PI3K) signaling being a common driver. However, the preclinical effectiveness of PI3K inhibitors has not necessarily translated to remarkable benefit in HNSCC patients. Thus, we sought to determine how precancerous keratinocytes influence HNSCC proliferation, cancer stem cell (CSC) maintenance, and response to PI3K inhibitors. We used the NOK keratinocyte cell line as a model of preneoplastic keratinocytes because it harbors two frequent genetic events in HNSCC, CDKN2A promoter methylation and TP53 mutation, but does not form tumors. NOK cell coculture or NOK cell-conditioned media promoted HNSCC proliferation, PI3K inhibitor resistance, and CSC phenotypes. SOMAscan-targeted proteomics determined the relative levels of >1300 analytes in the media conditioned by NOK cells and HNSCC cells ± PI3K inhibitor. These results demonstrated that NOK cells release abundant levels of ligands that activate epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor (FGFR), two receptor tyrosine kinases with oncogenic activity. Inhibition of EGFR, but not FGFR, blunted PI3K inhibitor resistance and CSC phenotypes induced by NOK cells. Our results demonstrate that precancerous keratinocytes can directly support neighboring HNSCC by activating EGFR. Importantly, PI3K inhibitor sensitivity was not necessarily a cancer cell-intrinsic property, and the tumor microenvironment impacts therapeutic response and supports CSCs. Additionally, combined inhibition of EGFR with PI3K inhibitor diminished EGFR activation induced by PI3K inhibitor and potently inhibited cancer cell proliferation and CSC maintenance.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  EGFR; HNSCC; PI3K; cancer stem cell; resistance; squamous cell carcinoma

Mesh:

Substances:

Year:  2022        PMID: 35417043      PMCID: PMC9233118          DOI: 10.1002/mc.23409

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   5.139


  60 in total

1.  Genetic progression model for head and neck cancer: implications for field cancerization.

Authors:  J Califano; P van der Riet; W Westra; H Nawroz; G Clayman; S Piantadosi; R Corio; D Lee; B Greenberg; W Koch; D Sidransky
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

2.  PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.

Authors:  Nnamdi Eze; Ju-Whei Lee; Dong-Hua Yang; Fang Zhu; Veronique Neumeister; Teresa Sandoval-Schaefer; Ranee Mehra; John A Ridge; Arlene Forastiere; Christine H Chung; Barbara Burtness
Journal:  Oral Oncol       Date:  2019-03-04       Impact factor: 5.337

Review 3.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

4.  Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.

Authors:  Anindita Chakrabarty; Violeta Sánchez; María G Kuba; Cammie Rinehart; Carlos L Arteaga
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

5.  Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

Authors:  J D Moyer; E G Barbacci; K K Iwata; L Arnold; B Boman; A Cunningham; C DiOrio; J Doty; M J Morin; M P Moyer; M Neveu; V A Pollack; L R Pustilnik; M M Reynolds; D Sloan; A Theleman; P Miller
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

6.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.

Authors:  Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis
Journal:  Cancer Discov       Date:  2013-04-25       Impact factor: 39.397

7.  Targeting BMI1+ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma.

Authors:  Demeng Chen; Mansi Wu; Yang Li; Insoon Chang; Quan Yuan; Mari Ekimyan-Salvo; Peng Deng; Bo Yu; Yongxin Yu; Jiaqiang Dong; John M Szymanski; Sivakumar Ramadoss; Jiong Li; Cun-Yu Wang
Journal:  Cell Stem Cell       Date:  2017-03-09       Impact factor: 24.633

8.  Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  José Baselga; Seock-Ah Im; Hiroji Iwata; Javier Cortés; Michele De Laurentiis; Zefei Jiang; Carlos L Arteaga; Walter Jonat; Mark Clemons; Yoshinori Ito; Ahmad Awada; Stephen Chia; Agnieszka Jagiełło-Gruszfeld; Barbara Pistilli; Ling-Ming Tseng; Sara Hurvitz; Norikazu Masuda; Masato Takahashi; Peter Vuylsteke; Soulef Hachemi; Bharani Dharan; Emmanuelle Di Tomaso; Patrick Urban; Cristian Massacesi; Mario Campone
Journal:  Lancet Oncol       Date:  2017-05-30       Impact factor: 41.316

9.  AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

Authors:  Sarat Chandarlapaty; Ayana Sawai; Maurizio Scaltriti; Vanessa Rodrik-Outmezguine; Olivera Grbovic-Huezo; Violeta Serra; Pradip K Majumder; Jose Baselga; Neal Rosen
Journal:  Cancer Cell       Date:  2011-01-06       Impact factor: 31.743

10.  Therapy-induced tumour secretomes promote resistance and tumour progression.

Authors:  Anna C Obenauf; Yilong Zou; Andrew L Ji; Sakari Vanharanta; Weiping Shu; Hubing Shi; Xiangju Kong; Marcus C Bosenberg; Thomas Wiesner; Neal Rosen; Roger S Lo; Joan Massagué
Journal:  Nature       Date:  2015-03-25       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.